ATAC - Quality of Life Sub-Protocol

Study identifier:1033IE/0029

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Randomised, Double-Blind, Parallel Group Trial to Assess Quality of Life with Arimidex Alone, Nolvadex Alone, or Arimidex and Nolvadex in Combination, when used as Adjuvant Treatment for Breast Cancer in Postmenopausal Women

Medical condition

Quality of Life

Phase

Phase 3

Healthy volunteers

Study drug

Anastrozole, Tamoxifen

Sex

Female

Actual Enrollment

308

Study type

Interventional

Age

45 Years +

Date

Study Start Date: 01 Apr 1998

Primary Completion Date: -

Study Completion Date: 01 Apr 2004

Study design

Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Other

Verification:

Verified 01 Dec 2013 by AstraZeneca Pharmaceuticals

Collaborators

Inclusion and exclusion criteria

No locations available

Arms	Assigned Interventions
Active Comparator: 1 Arimidex 1mg + Nolvadex placebo	Drug: Anastrozole 1mg, orally, once daily Other Name: Arimidex
Active Comparator: 2 Arimidex placebo + Nolvadex 20mg	Drug: Anastrozole 1mg, orally, once daily Other Name: Arimidex Drug: Tamoxifen 20mg, orally, once daily Other Name: Nolvadex
Active Comparator: 3 Arimidex 1mg + Nolvadex 20mg	Drug: Tamoxifen 20mg, orally, once daily Other Name: Nolvadex

"There is no result for the study"

Documents available

https://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_6111&studyid=1151&filename=CSR-1033ie-0029.pdf
Download
CSR-1033ie-0029.pdf
Download
Trial Results Summaries
Available here

Contacts

Contact

AstraZeneca Clinical Study

800-236-9933

information.center@astrazeneca.com